DexCom Inc. (NASDAQ:DXCM) today announced the election of Terrance H. Gregg to its Board of Directors.

Mr. Gregg served as President and Chief Operating Officer of MiniMed, Inc., a medical technology company focused on insulin pumps for people with diabetes, from October 1996 until its acquisition by Medtronic, Inc. in August 2001. Mr. Gregg served as a Vice President of Medtronic and President of Medtronic MiniMed after the acquisition until he retired in July 2002 and, subsequently, as a senior advisor to the diabetes business of Medtronic, Inc. until September 2004. Mr. Gregg formerly served as the Chairman of the American Diabetes Association (ADA) Research Foundation Board, is currently an Ambassador to the President of the University of Southern California, and serves on the board of directors of Amylin, Inc., LMS Medical Systems, Ltd. And Vasogen, Inc. Mr. Gregg received a B.S. in Zoology from Colorado State University.

"Terry is one of the most respected and successful business leaders in medical device technology, as well as a passionate advocate for people with diabetes. Terry brings a wealth of experience to DexCom, especially related to the process of commercializing a novel, new technology and product platform in the diabetes marketplace," said Andy Rasdal, President and CEO of DexCom Inc.

About DexCom Inc.

DexCom Inc., headquartered in San Diego, California, is developing continuous glucose monitoring systems for people with diabetes.